https://prabadinews.com/
  • October 8, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

Iza-Bren Receives FDA Breakthrough Therapy Designation for EGFR-Mutated NSCLC

Iza-Bren Receives FDA Breakthrough Therapy Designation for EGFR-Mutated NSCLC

The action is supported by 3 ongoing clinical trials, which are evaluating izalontamab brengitecan (iza-bren) in non–small cell lung cancer (NSCLC) and other diseases.

administrator

Related Articles